济民医疗(603222) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 decreased by 6.97% year-on-year, totaling RMB 682,669,168.73[2] - Net profit attributable to shareholders decreased by 49.17% year-on-year, amounting to RMB 28,415,048.97[2] - The net cash flow from operating activities decreased by 48.85% year-to-date, totaling RMB 44,287,950.98[2] - Basic earnings per share decreased by 47.71% for the current period, reported at RMB 0.0538[2] - The net profit attributable to shareholders for the year-to-date period decreased by 36.96% due to increased R&D investment and depreciation from new facilities[5] - The company reported a decrease of 32.47% in net profit after deducting non-recurring gains and losses for the year-to-date period[5] - The net profit for Q3 2024 was CNY 33,403,175.66, down from CNY 61,349,444.39 in Q3 2023, indicating a decline of about 45.5%[13] - The net profit attributable to shareholders of the parent company was CNY 28,415,048.97 in Q3 2024, down from CNY 45,076,348.04 in Q3 2023, a decrease of about 37.0%[14] - The basic earnings per share for Q3 2024 was CNY 0.0538, compared to CNY 0.0840 in Q3 2023, a decline of approximately 36.5%[14] - The total profit for Q3 2024 was CNY 34,843,573.99, down from CNY 64,619,210.81 in Q3 2023, a decrease of about 46.0%[13] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 2,427,594,076.87, a decrease of 2.11% compared to the previous year[3] - As of September 30, 2024, the company's total assets amounted to RMB 2,427,594,076.87, a decrease from RMB 2,479,979,435.44 at the end of 2023, reflecting a decline of approximately 2.1%[10] - The company's total liabilities decreased to RMB 453,363,887.01 from RMB 469,031,954.79, a reduction of about 3.3%[12] - The company's equity attributable to shareholders totaled RMB 1,572,374,694.74, a slight decrease from RMB 1,576,049,228.56, indicating a decline of about 0.2%[12] Cash Flow - The company's cash and cash equivalents decreased to RMB 190,594,807.75 from RMB 251,183,548.37, representing a decline of about 24.1%[10] - The net cash flow from operating activities was CNY 44,287,950.98, a decrease of 48.9% compared to CNY 86,587,048.29 in the previous year[15] - Cash inflow from investment activities totaled CNY 411,893,169.32, while cash outflow was CNY 500,107,098.00, resulting in a net cash flow of -CNY 88,213,928.68, an improvement from -CNY 193,887,935.85 year-over-year[15] - Total cash and cash equivalents at the end of the period were CNY 172,601,307.75, down from CNY 318,132,518.18, reflecting a decrease of 45.8%[16] - The net increase in cash and cash equivalents was -CNY 64,692,590.62, compared to -CNY 317,593,408.46 in the previous year, showing a significant improvement[16] Shareholder Information - The company has a total of 33,051 common shareholders as of the end of the reporting period[7] - The largest shareholder, Shuangge Group Co., Ltd., holds 23.82% of the shares, with 127,983,520 shares pledged[7] Operating Costs and Expenses - The total operating costs for Q3 2024 were CNY 651,011,799.90, an increase from CNY 619,320,318.07 in Q3 2023, representing a growth of approximately 5.3%[13] - Research and development expenses increased to CNY 30,296,180.81 in Q3 2024, compared to CNY 21,841,589.34 in Q3 2023, reflecting a rise of approximately 38.5%[13] - The company's tax expenses for Q3 2024 were CNY 1,440,398.33, down from CNY 3,269,766.42 in Q3 2023, a decrease of approximately 55.8%[13] - Other comprehensive income after tax for Q3 2024 was CNY -372,317.12, compared to CNY 1,836,156.73 in Q3 2023, indicating a significant change[14] Revenue Growth - For the first three quarters of 2024, the company reported total revenue of RMB 682,669,168.73, a slight increase from RMB 677,627,000.76 in the same period of 2023, representing a growth of approximately 0.6%[12] - The total revenue from sales of goods and services for the first nine months of 2024 was CNY 687,220,718.81, an increase from CNY 674,785,941.93 in the same period of 2023[14]